In vitro induction of human immunodeficiency virus type 1 variants resistant to 2'-β-fluoro-2',3'-dideoxyadenosine

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1313-1318

  Tanaka, Masatoshi ^a,c   Srinivas, Ranga V ^b   Ueno, Takamasa ^a,d   Kavlick, Mark F ^a   Hui, Ferdinand K ^a   Fridland, Arnold ^b   Driscoll, John S ^a   Mitsuya, Hiroaki ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c KYUSHU UNIVERSITY   (Japan)

^d JAPAN ENERGY CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CODON; CROSS RESISTANCE; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STRUCTURAL GENE; VIRUS INDUCTION; VIRUS RESISTANCE;

EID: 0031009294     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1313     Document Type: Article

References (39)

1. Eron, J. J., Y.-K. Chow, A. M. Caliendo, J. Videler, K. M. Devore, T. P. Cooley, H. A. Liebman, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1993. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37:1480-1487.
2. Fitzgibbon, J. E., R. E. Howell, C. A. Harberzettl, S. J. Sperber, D. J. Gocke, and D. T. Dubin. 1992. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
3. Gao, Q., Z. Gu, M. A. Parniak, J. Cameron, N. Cammack, C. Boucher, and M. A. Wainberg. 1993. The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:1390-1392.
4. Gao, Q., Z. Gu, M. A. Parniak, X. Li, and M. A. Wainberg. 1992. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine. J. Virol. 66:12-19.
5. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
6. Gao, W. Y., T. Shirasaka, D. G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-2333.
7. Gong, Y.-F., D. R. Marshall, R. V. Srinivas, and A. Fridland. 1994. Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 38:1683-1687.
8. Gu, Z., Q. Gao, H. Fang, H. Salomon, M. A. Parniak, E. Goldberg, J. Cameron, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
9. Hitchcock, M. J. M., K. Woods, H. DeBoeck, and H.-T. Ho. 1990. Biochemical pharmacology of 2′-fluoro-2′,3′-dideoxyarabinosyladenine, an inhibitor of HIV with improved metabolic and chemical stability over 2′,3′-dideoxyadenosine. Antivir. Chem. Chemother. 1:319-327.
10. Husson, R. N., T. Shirasaka, K. M. Butler, P. A. Pizzo, and H. Mitsuya. 1993. High-level resistance to zidovudine but not to zalcitabine or didanosine in human immunodeficiency virus from children receiving antiretroviral therapy. J. Pediatr. 123:9-16.
11. Iversen, A. K. N., R. W. Shafer, K. Wehrly, M. A. Winters, J. I. Mullins, B. Chesebro, and T. C. Merigan. 1996. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J. Virol. 70:1086-1090.
12. Kavlick, M. F., T. Shirasaka, J. Pluda, F. K. Hui, R. Yarchoan, and H. Mitsuya. 1995. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving therapy with (-)-3′-thia-2′,3′-dideoxycytidine (3TC). Antivir. Res. 28:133-146.
13. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice, and T. A. Steitz. 1992. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
14. Kozal, M. J., R. W. Shafer, M. A. Winters, D. A. Katzenstein, and T. C. Merigan. 1993. A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167:526-532.
15. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
16. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453.
17. Mahalingam, M., A. Pozniak, T. J. McManus, D. Vergani, and M. Peakman. 1995. Cell cycling in HIV infection: analysis of in vivo activated lymphocytes. Clin. Exp. Immunol. 102:481-486.
18. Marquez, V. E., C. K.-H. Tseng, J. A. Kelly, H. Mitsuya, S. Broder, J. S. Roth, and J. S. Driscoll. 1987. 2′,3′-Dideoxy-2′-fluoro-ara-A. An acid-stable purine nucleoside active against human immunodeficiency virus (HIV). Biochem. Pharmacol. 36:2719-2722.
19. Marquez, V. E., C. K.-H. Tseng, H. Mitsuya, S. Aoki, J. A. Kelley, J. H. Ford, J. S. Roth, S. Broder, D. G. Johns, and J. S. Driscoll. 1990. Acid-stable 2′-fluoro purine dideoxynucleotides as active agents against HIV. J. Med. Chem. 33:978-985.
20. Meyers, G., B. Korber, B. H. Hahn, K. T. Jeang, J. W. Mellors, F. E. McCutchan, L. E. Henderson, and G. N. Pavlakis (ed.). 1996. Human retroviruses and AIDS 1995. Los Alamos National Laboratory, Los Alamos, N.Mex.
21. Mitsuya, H., and R. Yarchoan. 1994. Development of antiretroviral therapy for AIDS and related disorders, p. 721-742. In S. Broder, T. Merigan, and D. Bolognesi (ed.), Textbook of AIDS medicine. Williams & Wilkins, Baltimore, Md.
22. Montaner, J. S. G., J. Singer, M. T. Schechter, J. M. Raboud, and M. A. Wainberg. 1993. Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicentre Canadian AZT trial. AIDS 7:189-196.
23. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
24. Reichman, R. C., N. Tejani, J. L. Lambert, J. Strussenberg, W. Bonnez, B. Blumberg, L. Epstein, and R. Dolin. 1993. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antivir. Res. 20:267-277.
25. Richman, D. D., V. A. Johnson, D. L. Mayers, T. Shirasaka, M. O'Brien, and H. Mitsuya. 1993. In vitro evaluation of experimental agents for anti-HIV activity, p. 12.9.1-12.9.21. In J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, vol. 1. John Wiley & Sons, New York, N.Y.
26. Rizza, P., S. M. Santini, M. Logozzi, C. Lapenta, P. Sestili, G. Gherardi, R. Lande, M. Spada, S. Parlato, F. Belardelli, and S. Fais. 1996. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. J. Virol. 70:7958-7964.
27. Ruxrungtham, K., E. Boone, H. Ford, Jr., J. S. Driscoll, R. T. Davey, Jr., and H. C. Lane. 1996. Potent activity of 2′-β-fluoro-2′,3′-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Antimicrob. Agents Chemother. 40:2369-2374.
28. Schinazi, R. F., R. M. Lloyd, Jr., M.-H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
29. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. R. Meyer, P. Gupta, S. Rasheed, R. Coombs, and T. C. Merigan. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
30. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin, J.-L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39: 2555-2559.
31. Shirasaka, T., M. F. Kavlick, T. Ueno, W.-Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:2398-2402.
32. Shirasaka, T., R. Yarchoan, M. O'Brien, R. Husson, B. Anderson, E. Kojima, S. Broder, and H. Mitsuya. 1993. Changes in drug-sensitivity of human immunodeficiency virus type 1 during therapy, with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90:562-566.
33. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
34. Stoltz, M. L., M. El-hawari, L. Little, A. C. Smith, J. E. Tomaszewski, and C. K. Grieshaber. 1989. Pharmacokinetics and bioavailability of 2′,3′-dideoxynucleoside anti-AIDS agents in beagle dogs. Proc. Am. Assoc. Cancer Res. 30:535.
35. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
36. Tudor-Williams, G., M. St. Clair, R. McKinney, M. Maha, E. Walter, S. Santacrose, M. Mintz, K. O'Donnell, T. Rudoll, C. L. Vavro, E. M. Connor, and C. M. Wilfert. 1992. HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339:15-19.
37. 36a. Ueno, T., and H. Mitsuya. Unpublished data.
38. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleotides. J. Biol. Chem. 270:23605-23611.
39. Zhang, D., A. M. Caliendo, J. J. Eron, K.M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.